Avalo Therapeutics (AVTX) Net Margin (2016 - 2025)
Avalo Therapeutics posted quarterly Net Margin of 23254.24% for Q4 2025, down 484851.0% year-on-year from N/an in Q4 2024, and down 26.34% on a QoQ basis from 18405.73% in Q4 2024.
Avalo Therapeutics (AVTX) has 9 years of Net Margin data on file, last reported at 23254.24% in Q4 2025.
- For the quarter ending Q4 2025, Net Margin fell 484851.0% year-over-year to 23254.24%; the trailing twelve-month figure through Dec 2025 stood at 15651.8% (down 768604.0% YoY), and the FY2025 full-year result was 132642.37%, down 12467661.0% from the prior year.
- Net Margin for Q4 2025 stood at 23254.24%, down from 18405.73% in the prior quarter.
- Across five years, Net Margin topped out at 9251.81% in Q3 2024 and bottomed at 23254.24% in Q4 2025.
- The 4-year median for Net Margin is 1274.18% (2023), against an average of 3588.02%.
- Peak annual rise in Net Margin reached 1146706 bps in 2024, while the deepest fall reached 1697526 bps in 2024.
- A 4-year view of Net Margin shows it stood at 29.68% in 2021, then plunged by 4720 bps to 1430.47% in 2023, then sank by 1187 bps to 18405.73% in 2024, then retreated by 26 bps to 23254.24% in 2025.
- The last three Net Margin figures came in at 23254.24% (Q4 2025), 18405.73% (Q4 2024), and 9251.81% (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.65% |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23,254.24% |
| Dec 31, 2024 | -18,405.73% |
| Sep 30, 2024 | 9,251.81% |
| Dec 31, 2023 | -1,430.47% |
| Sep 30, 2023 | -2,215.25% |
| Jun 30, 2023 | -1,274.18% |
| Mar 31, 2023 | -2,095.79% |
| Dec 31, 2021 | -29.68% |
| Sep 30, 2021 | 5.63% |
| Jun 30, 2021 | 2.06% |
| Mar 31, 2021 | -22.41% |
| Dec 31, 2020 | 33.33% |
| Sep 30, 2020 | -17.82% |
| Jun 30, 2020 | -34.01% |
| Mar 31, 2020 | 37.69% |
| Dec 31, 2019 | 1,249.08% |
| Sep 30, 2019 | -49.33% |
| Jun 30, 2019 | -264.30% |
| Mar 31, 2019 | -88.95% |
| Dec 31, 2018 | 12.36% |
| Sep 30, 2018 | -603.80% |
| Jun 30, 2018 | -125.54% |
| Mar 31, 2018 | -86.61% |
| Dec 31, 2017 | -161.78% |
| Sep 30, 2017 | 74.77% |
| Jun 30, 2017 | -1,139.74% |
| Mar 31, 2017 | -510.31% |
| Dec 31, 2016 | -900.39% |
| Sep 30, 2016 | -1,918.75% |
| Jun 30, 2016 | -555.74% |